This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chiou, R.-K. Articles by Lange, P. H. Search for Related Content PubMed PubMed Citation Articles by Chiou, R.-K. Articles by Lange, P. H.

Localization of Human Renal Cell Carcinoma Xenografts with a Tumor-preferential Monoclonal Antibody¹

Departments of Urologic Surgery [R-K. C., R. L. V., R. V. C., J. M. G., P. H. L.] and Microbiology [R. L. V.], University of Minnesota Medical Center, Minneapolis, Minnesota 55455 and Veterans Administration Medical Center, Minneapolis, Minnesota 55417 [R. L. V., M. K. E., R. B. S., E. W. A., P. H. L.]

We previously described an immunoglobulin G1 monoclonal antibody (UMVA-RCC-A6H) that is highly reactive with human renal cell carcinoma (RCC) and has little cross-reactivity to other cell types both normal and malignant. In efforts detailed herein, radiolabeled A6H selectively localized to RCC xenografts and provided high resolution images of the xenografts. Also, A6H clearly discriminated between RCC xenografts and other human tumor xenografts. Consistent images of RCC xenografts (>60 mg) were obtained without background subtraction. The amount of radiolabeled A6H in the tumor usually ranged from five to twenty times that of the blood. Normal mouse tissues, abscesses, and other human tumor xenografts contained less radiolabel per mg than did blood. A control monoclonal antibody of the same isotype failed to exhibit any localization in xenografts or normal tissues. Approximately 40% of the radiolabeled A6H dose per g was localized in the RCC xenograft 2 days after injection, although at the time of imaging about 60% of the radiolabel remaining in the mouse was associated with the xenograft. These results demonstrate that a RCC restrictive monoclonal antibody does specifically localize to RCC xenografts and supports the hope that this approach may have clinical value for diagnosis, staging, or treatment.

¹ Supported in part by Veterans Administration Medical Research funds and American Cancer Society Grants 05417 and 00757.

² To whom requests for reprints should be addressed, at Veterans Administration Medical Center, 54th Street and 48th Avenue S., Minneapolis, MN 55417.

Received 1/14/85. Revised 8/16/85. Accepted 8/21/85.